The Pathology of Mental Defect and Disorder [Abridged] Professor A N Davison (Department ofNeurochemistry, Institute ofNeurology, Queen Square, London WC] 3BG) Mental Retardation and the Biochemistry of the Developing Brain Different overlapping stages can be recognized in development of the central nervous system. Following early embryological changes the adult neuronal population is largely established before glial proliferation is maximal. In man estimation of DNA suggests that, normally, formation of nerve cells is essentially a prenatal process, whereas multiplication of glia is perinatal (Dobbing 1971 ). These changes occur at different rates in various areas of the nervous system, the cerebellum being one of the last to develop. Postnatal growth can be ascribed to ramification of dendrites, establishment of synaptic connexions and the long-drawn-out process of myelination. Deposition of myelin, particularly in white matter, accounts for a high proportion of the dry weight increase in the later stages of brain development. It has frequently been observed that amyelination results from certain nutritional deficits or pathological conditions affecting brain and mental development. For this reason Davison & Dobbing (1966) suggested that myelination may be regarded as a vulnerable period, quite mild stresses producing irreversible structural changes. Although reduced myelin synthesis is the most obvious defect, this may simply reflect other more subtle, but perhaps more harmful, changes in the brain's architecture, affecting intelligencefor example, reduction in the number of synaptic endings.
In accordance with the vulnerable period concept, it is recognized that in certain aminoacidurias, and in hypothyroidism, the first few months after birth are critical for subsequent intellectual development. Brain damage, especially amyelination, frequently accompanies untreated phenylketonuria, leucinosis, hyperprolinemia and similar conditions, and subsequent late dietary regimes fail to reverse the deficiencies in the absolute amount of myelin (Prensky et al. 1968) . It also appears that reversible changes accompany amino acid imbalance. For example, in leucinosis clinical observations indicate rapid behavioural improvement on diet, with precipitation of symptoms when excess oral leucine is given (Snyderman 1971) .
Structural damage to the developing brain in the aminoacidurias has been variously attributed to inhibition of lipid or protein biosynthesis. However, it seems unlikely that the effects of amino acid imbalance are primarily on synthesis of cerebral lipids. In experimental animals given large doses of phenylalanine for a prolonged period reduced lipid synthesis is observed (Barbato et al. 1968 , Shah & McKean 1968 , Shah et al. 1968 ). Previous claims that amino acid imbalance interferes with protein synthesis are also difficult to justify. This is because experimental design must allow for the fact that excess of one amino acid in the blood can inhibit entry into the brain of others whose transport into the amino acid pool is mediated by a common carrier system. Excess phenylalanine interferes with entry of such essential amino acids as leucine, methionine and tryptophan. To study the effects of experimental amino acid imbalance on brain protein synthesis, incorporation of label from 14C amino acid must be related to its specific activity in the brain acid soluble pool. In order to meet this requirement we examined the acute effects of high levels of phenylalanine on brain protein synthesis, using an amino acid whose transport is not affected by phenylalanine. When 14C-glycine was Monoamines and Mental Disease Charles Darwin said: 'I have no faith in anything short of actual measurement and the rule of three.' But in the central nervous system, as elsewhere, arbitrary selection processes make a mock of objectivity; we choose to measure the things that are easy to measure and tend to forget those that are not. 5-hydroxytryptamine, for instance, by virtue of its 5-hydroxyl group, possesses a specific fluorescence in strong acid denied to its unhydroxylated analogue, tryptamine, and tryptamine (Martin et al. 1971 ) is an unknown quantity in the central nervous system; the catecholamines, with their two adjacent hydroxyl groups, adsorb conveniently on to alumina but the monophenolic phenylethylamines and -ethanolamines do not and, as a consequence, have a token literature only to represent them. Very recently, however, we have been in the throes of a methodological revolution and it is now possible to quantify accurately vast numbers of relatively undistinguished molecules. Whilst immunoassay procedures have yet to prove their usefulness for molecules as small as the monoamines, combined gas chromatography-mass spectrometry, perhaps with the additional refinement of mass fragmentography (Hammar et al. 1969) , is well suited to measure these compounds with accuracy and specificity. An information explosion appears to be inevitable! And yet it would be a pity for the pendulum to swing to the other extreme, and for the role of 5-hydroxytryptamine and the catecholamines to be submerged in a welter of new data; there is still much to implicate them in the pathogenesis of mental disorder (Himwich 1970) . The structural similarity of many hallucinogens to these monoamines, e.g. lysergide, bufotenine, psilocybin or harmaline to 5-hydroxytryptamine, mescaline or dimethoxyamphetamine to dopamine, has, by analogy, initiated a search for an endogenous psychotomimetic compound as the causative agent for schizophrenia. But all attempts to identify such a compound, whether as adrenochrome, dimethoxyphenylethylamine or many others, have so far met with scant success (Weil-Malherbe & Szara 1971) .
A hypothesis involving some disturbance at the level of the putative dopamine receptor, based on the similarity between some of the clinical features of schizophrenia and the pharmacological derangement (model psychosis) associated with amphetamine overdosage, at present holds the centre of the stage (e.g. Randrup & Munkvad 1967). It is given flesh by the ability of such drugs as pimozide (Morris et al. 1970), 'central dopamine receptor' blockers, to attenuate or alleviate the clinical features of schizophrenia. But there is no shortage of hypotheses: one of the most recent involves the endogenous generation of toxic concentrations of 6-hydroxydopamine (Stein & Wise 1971) .
The action of the various antidepressive drugs similarly appears to be modulated by alterations in monoamine function; perhaps the most impressive linking evidence is the profound lightening of affect brought about by monoamine oxidase inhibiting drugs in depressive patients. These drugs show great variation in their antidepressive action (Davis 1965), perhaps reflecting their differing ability to inhibit a specific monoamine oxidase isoenzyme at a localized anatomical site (Sandler et al. 1971) . Such studies may eventually help to establish the identity and crucial concentration of the amine or amines indispensable to a normal mental state. With newer measuring techniques, the whole problem is likely to become more rather than less complex before its final solution.
